Movement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat

Market Focus08-12 23:57

On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and better-than-expected second-quarter results.

On the regulatory front, Moderna announced that its seasonal influenza vaccine mFLUSIVA received U.S. FDA approval for use in adults aged 50 and above, marking the company's fourth approved product in the U.S. and the first-ever mRNA vaccine to enter the flu market. The company expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with regulatory reviews ongoing in Australia, Canada, and Europe.

On the earnings front, Moderna reported Q2 EPS of -$1.97, beating the FactSet consensus estimate of -$2.01, while revenue of $145 million significantly exceeded the $102.9 million estimate. The company reiterated its target of 10% year-over-year revenue growth. Multiple investment banks recently raised price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190141929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190141929","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat","media":"Market Focus","content":"<p><p>On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and better-than-expected second-quarter results.</p><p>On the regulatory front, Moderna announced that its seasonal influenza vaccine mFLUSIVA received U.S. FDA approval for use in adults aged 50 and above, marking the company's fourth approved product in the U.S. and the first-ever mRNA vaccine to enter the flu market. The company expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with regulatory reviews ongoing in Australia, Canada, and Europe.</p><p>On the earnings front, Moderna reported Q2 EPS of -$1.97, beating the FactSet consensus estimate of -$2.01, while revenue of $145 million significantly exceeded the $102.9 million estimate. The company reiterated its target of 10% year-over-year revenue growth. Multiple investment banks recently raised price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Moderna, Inc. Rises 5.17% in Regular Trading, First mRNA Flu Vaccine FDA Approval Combined with Q2 Earnings Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-12 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and better-than-expected second-quarter results.</p><p>On the regulatory front, Moderna announced that its seasonal influenza vaccine mFLUSIVA received U.S. FDA approval for use in adults aged 50 and above, marking the company's fourth approved product in the U.S. and the first-ever mRNA vaccine to enter the flu market. The company expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with regulatory reviews ongoing in Australia, Canada, and Europe.</p><p>On the earnings front, Moderna reported Q2 EPS of -$1.97, beating the FactSet consensus estimate of -$2.01, while revenue of $145 million significantly exceeded the $102.9 million estimate. The company reiterated its target of 10% year-over-year revenue growth. Multiple investment banks recently raised price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"","article_id":"1190141929","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190141929","pubTimestamp":1786550226,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"动态警报|Moderna, Inc. 常规交易中上涨 5.17%，首个 mRNA 流感疫苗获得 FDA 批准，第二季度盈利超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1},"content_text":"On August 12, Moderna, Inc. rose 5.17% in regular trading, trading at $63.70 per share, with turnover of $142 million. The rally was driven by the dual catalysts of its mRNA flu vaccine approval and better-than-expected second-quarter results.On the regulatory front, Moderna announced that its seasonal influenza vaccine mFLUSIVA received U.S. FDA approval for use in adults aged 50 and above, marking the company's fourth approved product in the U.S. and the first-ever mRNA vaccine to enter the flu market. The company expects the vaccine to be available at select retail channels in the coming weeks for the 2026-2027 respiratory virus season, with regulatory reviews ongoing in Australia, Canada, and Europe.On the earnings front, Moderna reported Q2 EPS of -$1.97, beating the FactSet consensus estimate of -$2.01, while revenue of $145 million significantly exceeded the $102.9 million estimate. The company reiterated its target of 10% year-over-year revenue growth. Multiple investment banks recently raised price targets, with Goldman Sachs adjusting to $67 and Jefferies to $60, both maintaining Hold ratings.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190141929","isCrawlerRequest":true}